Abstract 176P
Background
Neuroendocrine tumors are tumors that originate from endocrine cells in various organs, and show very heterogeneous characteristics, and their incidence is gradually increasing. Among them, neuroendocrine tumors originating from the pancreas are divided into functional tumors and non-functional tumors according to the secretion function of hormones. Therefore, we aimed to find protein biomarkers for diagnosis and differential diagnosis of pancreatic neuroendocrine tumor (PNET) through proteomic analysis of human blood.
Methods
A total of 60 human plasma samples were collected from 17 PNETs, 23 PDACs and 20 healthy donors, and liquid chromatography-mass spectrometry (LC-MS) proteomics analysis was performed on 60 human raw data. Identification and label-free quantification were performed through the swissprot protein sequence database. To investigate the function of CD163 among these three biomarker candidates, CD163-expressing cell lines were generated and 3 kinds of experiments were conducted. Additionally, to investigate the correlation between CD163 expression and cells, CBC analysis was performed by collecting blood and tumor tissues from mice transplanted with PNET and PDAC cell lines.
Results
An average of 549 protein lists were secured through LC-MS proteomics analysis using 60 samples, proteomes increased or decreased with disease were analyzed and classified through quantitative evaluation, and ACTR3, CD163, and LECT2 increased in PNET were selected as candidates for diagnostic biomarkers. The diagnostic AUC to differentiate PNET from HD was 0.971 for CD163 and the differential AUC to distinguish between PNET and PDAC was 0.870 for CD163. Additionally, CD163 was confirmed in the blood and tumor tissues of mice transplanted with PNET and PDAC cell lines, and significant results were obtained in PNET. Among the three biomarkers, CD163 was knocked-in to the PNET cell line to confirm the effect of CD163 on PNET.
Conclusions
These three markers will be used to identify molecular biological mechanisms for the generation and progression of PNET, and to study their function as markers that can simultaneously predict diagnosis and treatment response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract